Who Paid My Doc
Sumati Gupta
Geriatric Medicine Salt Lake City, UT Medical Doctor
NPI 1003906603 CMS profile 363468
1950 Circle Of Hope, Clinic 2B, Salt Lake City, UT 84112
General payments
$941
Research payments
$4,038
Ownership & investment interest
$0
Research they led as principal investigator
$1,926,447
Through program year 2025, Sumati Gupta of Salt Lake City, UT is reported in the CMS Open Payments database as having received $941 across 5 general payments and $4,038 in research payments paid to them. Separately, studies naming them as principal investigator received $1,926,447 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 91st percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $21 | 1 | |
| 2023 | General | $184 | 2 | |
| 2023 | Research | $3,459 | 6 | |
| 2022 | Research | $579 | 2 | |
| 2019 | General | $736 | 2 |
Beside peers
- Sumati Gupta
- Geriatric Medicine median
- Middle half of Geriatric Medicine
- National median
In program year 2025, general payments to Sumati Gupta were reported at $21. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.
Show as a table
| Year | Sumati Gupta | Geriatric Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $736 | $122 | $40–$435 | $163 |
| 2020 | $0 | $98 | $25–$349 | $114 |
| 2021 | $0 | $125 | $34–$441 | $132 |
| 2022 | $0 | $124 | $36–$408 | $149 |
| 2023 | $184 | $121 | $41–$383 | $160 |
| 2024 | $0 | $134 | $41–$435 | $164 |
| 2025 | $21 | $123 | $35–$408 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 15 drugsPart D claims
322
Drug cost
$1,161,757
Branded share of claims
33.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Welireg Belzutifan | Brand | 28 | $666,408 | |
| Inlyta Axitinib | Brand | 11 | $230,519 | |
| Xtandi Enzalutamide | Brand | 24 | $157,932 | |
| Orgovyx Relugolix | Brand | 26 | $65,591 | |
| Eliquis Apixaban | Brand | 18 | $21,175 | |
| Abiraterone Acetate | Generic | 29 | $18,599 | |
| Prochlorperazine Maleate | Generic | 25 | $417 | |
| Prednisone | Generic | 52 | $269 | |
| Levothyroxine Sodium | Generic | 25 | $230 | |
| Potassium Chloride | Generic | 12 | $128 |
The 10 drugs with the highest cost, of 15 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 8 billing codesPaid by Medicare
$29,079
Medicare patients
78
Services billed
511
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Cancer | 75% | |
| Chronic kidney disease | 45% | |
| Diabetes | 38% | |
| Arthritis | 38% | |
| Ischemic heart disease | 35% | |
| Depression | 28% | |
| Heart failure | 24% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
13 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Geriatric Medicine in Utah
Alison Schlisman
Geriatric Medicine · Salt Lake City, UT
Danesh Rahimi
Geriatric Medicine · Salt Lake City, UT
Michael Farrell
Geriatric Medicine · Heber City, UT
Ronak Iqbal
Geriatric Medicine · Salt Lake City, UT
Nicholas Brening
Geriatric Medicine · Salt Lake City, UT
Rachael Stubbs
Geriatric Medicine · Taylorsville, UT
Related records
Geriatric Medicine in Utah
Practitioners in the same specialty and state, ranked by reported value.
All Geriatric Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Utah
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.